The onset of the COVID-19 pandemic brought unprecedented disruption to drug development.

While sponsors rushed to reallocate resources to develop treatments and vaccines, many faced challenges associated with travel restrictions, site closures, self-isolation protocols, emerging regulatory guidance, and an understandably fearful and reluctant patient population.

Read more on this article by clicking here.